TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. read more

EMPLOYEE PARTICIPANTS: 26

TOTAL RATINGS: 504

CEO: Michael S. Weiss

HR or Marketing? Claim Your Free Employer Account

TG Therapeutics Awards

TG Therapeutics has not won any awards as of yet. However, based on 504 ratings and 26 participants, employees at TG Therapeutics are satisfied with their work experience. The overall culture score, 76/100 or B+, incorporates employee ratings based on their feedback on the Compensation, Happiness, Meetings and more. Also, TG Therapeutics ranks in the top 20% of similar size companies and top 20% of companies on Comparably

Awards

Comparably Awards are provided yearly to top performing company cultures based on real feedback from their employees.

TG Therapeutics hasn't won any awards yet.

Top

20%

TG Therapeutics currently ranks in the Top 20% of similarly sized companies on Comparably

Top

20%

TG Therapeutics currently ranks in the Top 20% of nearby companies

2nd

TG Therapeutics currently ranks 2nd place versus 3 competitors

Help Your Company Win 2025 Awards